BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Applied Data Research Release: Evolving Technology Targeting Drug Delivery at the Cellular Level


2/4/2008 10:59:35 AM

(Nashua, NH) - The ability to deliver drugs to specific cells has long been regarded as the next major milestone in drug therapeutics. Targeting drugs to the cellular level is expected to minimize drug side effects, expand their use and improve patient outcomes. Patient compliance remains a major obstacle to improving the clinical outcomes of efficacious drugs. While a number of factors contribute to compliance issues, avoidance of drug side effects is known to be a key determinant.

More than thirty companies are now working to develop targeted delivery methods that pinpoint specific cells. Most of these approaches rely on the use of ligands capable of binding to cell surface receptors preferentially expressed on targeted cells. Other promising technologies include target-cell activation and energy activation of a localized drug.

Responding to the unpleasant and even debilitating side effects associated with cancer drug therapeutics, the majority of targeted drug delivery efforts in development have oncology drugs as their focus. While the current generation of targeted delivery platforms is designed for adaptability to a range of drugs, the degree of tailoring required is still somewhat significant. We expect clinical experience to enable optimized versions of several platforms that will reduce time-to-market going forward.

These and other conclusions are the subject of a comprehensive report. The report documents and analyzes the results of a recent assessment of the evolving targeted drug delivery sector conducted by Applied Data Research. More information is also available at www.applieddata.org .

About Applied Data Applied Data Research is a healthcare therapeutics consulting firm focused on medical market strategies, product commercialization, venture development, and market research. We assist medical market participants in achieving their business objectives through the creation of detailed business development strategies, product commercialization programs, and comprehensive market and technology research and analysis.

Contact: Greg Stone Voice: 603-595-6225 www.applieddata.org

Source: Applied Data Research



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES